This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Reasons Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
BSXPositive Net Change ECLPositive Net Change DVANegative Net Change AVTRPositive Net Change
medical medical-devices
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
BHVNNegative Net Change ENTXNegative Net Change IMVTNegative Net Change ALXONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Strength in HSA Likely to Aid HealthEquity's (HQY) Q1 Earnings
by Zacks Equity Research
Continued strength in HSA, aided by transfers of HSA Assets from BenefitWallet, is likely to have boosted HealthEquity's (HQY) top line in the fiscal first quarter.
MUNegative Net Change ALGNPositive Net Change HQYPositive Net Change BBWIPositive Net Change
earnings medical medical-devices
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
DXCMPositive Net Change TNDMNegative Net Change MEDPPositive Net Change HIMSNegative Net Change
medical medical-devices
Do Options Traders Know Something About ICON (ICLR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ICON (ICLR) stock based on the movements in the options market lately.
ICLRPositive Net Change
medical
Do Options Traders Know Something About Humana (HUM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Humana (HUM) stock based on the movements in the options market lately.
HUMPositive Net Change
medical
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
RMDNegative Net Change CRLNegative Net Change MEDPPositive Net Change HIMSNegative Net Change
medical medical-devices
Implied Volatility Surging for Abbot Laboratories (ABT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Abbot Laboratories (ABT) stock based on the movements in the options market lately.
ABTPositive Net Change
medical medical-devices
Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?
by Zacks Equity Research
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
ABBVPositive Net Change
medical
Stryker (SYK) Issues Safety Notice for Its Total Knee System
by Zacks Equity Research
Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.
BSXPositive Net Change ECLPositive Net Change SYKPositive Net Change ALGNPositive Net Change
medical medical-devices
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change PACBNegative Net Change
medical medical-devices
Centene (CNC) Expands CHS Network, Shifts AcariaHealth Facility
by Zacks Equity Research
Centene's (CNC) subsidiaries, CHS and AcariaHealth, enhance patient outcomes with CHS' CIPA entering Virginia and AcariaHealth's pharmacy facility relocating to Chesterfield, thereby expanding CNC's capabilities.
CNCPositive Net Change LNTHPositive Net Change PNTGPositive Net Change OGNPositive Net Change
medical
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
RPRXPositive Net Change AGIONegative Net Change HRTXPositive Net Change ARQTNegative Net Change
medical
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
by Zacks Equity Research
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
INSMNegative Net Change HRTXPositive Net Change MRNSNegative Net Change ARQTNegative Net Change
biotechs medical
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant
by Zacks Equity Research
Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.
RMDNegative Net Change MEDPPositive Net Change EHCPositive Net Change IINNNegative Net Change
medical medical-devices
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
by Zacks Equity Research
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
RMDNegative Net Change EXASPositive Net Change MEDPPositive Net Change EHCPositive Net Change
medical
Philips (PHG) Boosts Medical Imaging Footprint With New Move
by Zacks Equity Research
Philips (PHG) expands its international footprint with the wide availability of VeriSight Pro 3D to several Hong Kong hospitals, strengthening its Diagnosis & Treatment segment.
PHGNegative Net Change DVANegative Net Change ALCPositive Net Change EHCPositive Net Change
medical medical-devices
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
by Zacks Equity Research
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
CORTNegative Net Change NERVPositive Net Change MRNSNegative Net Change KRYSNegative Net Change
medical
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
by Zacks Equity Research
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
AZNPositive Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health Services, Acadia Healthcare and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Tenet Healthcare, Universal Health Services, Acadia Healthcare and Community Health Systems are part of the Zacks Industry Outlook article.
UHSPositive Net Change THCPositive Net Change CYHPositive Net Change HCAPositive Net Change ACHCPositive Net Change
medical
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
by Zacks Equity Research
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
BMYPositive Net Change PRTAPositive Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
INGNPositive Net Change HQYPositive Net Change CGCNegative Net Change HIMSNegative Net Change
cannabis medical medical-devices
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
by Zacks Equity Research
Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.
HCATPositive Net Change HIMSNegative Net Change ENOVPositive Net Change
medical
5 Stocks With Recent Price Strength That Have More Upside Left
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are SRTS, DBD, ATGE, DY, SGC.
DBDNegative Net Change DYNegative Net Change SGCPositive Net Change ATGENegative Net Change SRTSNegative Net Change
construction consumer-discretionary internet medical
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
BAXPositive Net Change DVANegative Net Change ALGNPositive Net Change EHCPositive Net Change
medical medical-devices